Melanoma-pancreatic cancer syndrome

CDKN2A - melanoma-pancreatic cancer syndrome ¹

This test is available for the following conditions:

• Conditions > Skin > Melanoma-pancreatic cancer syndrome
• Conditions > Oncogenetics > Melanoma-pancreatic cancer syndrome

This product is also part of the following panels:

• Hereditary cancer panel
• Mendelian inherited disorders panel with genome wide CNV analysis
• Panel hereditary pancreatic cancer (BRCA1, BRCA2, PALB2, ATM, CDKN2A, MLH1, MSH2, MSH6, PMS2, STK11)
• panel Melanoma, basic (CDKN2A, CDK4, MITF p.(Glu318Lys)¹
• panel Melanoma, basic (CDKN2A, CDK4, MITF p.(Glu318Lys)¹
• panel Melanoma, extensive (CDKN2A, CDK4, MITF p.(Glu318Lys), BAP1, POT1, TERT promoter)¹

Turnaround time
Complete analysis: 8 weeks / Targeted analysis: 4 weeks

Method

• Sequence analysis of all coding exons and flanking intron-exon boundaries

OMIM: 600160
Performing laboratory: Maastricht UMC+
Authorized material(s): EDTA blood, Isolated DNA, Buccal mucous membrane

---